The dominant negative form of IKKβ, which lacks conserved lysine residue that is necessary for its catalytic activity, or non-degradable IκBα, which lacks its serine phosphorylation sites, reduced inflammatory cytokine expression and tumor growth in vitro and in vivo [21, 25, 26], suggesting that IKKβ inhibition represents a very promising therapeutic strategy for cancer. This evidence concerns the gene IKBKB and cancer.